Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
preS hepatitis B surface antigen + Advax-3
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
preS hepatitis B surface antigen + Advax-3 (Hepadvax) is a recombinant protein subunit vaccine candidate developed by Vaxine Pty Ltd for the prevention and treatment of Hepatitis B virus (HBV) infection. The vaccine incorporates a large surface protein containing the preS1, preS2, and S domains, which provides a broader range of B- and T-cell epitopes compared to conventional S-only vaccines. It is formulated with Advax-3, a proprietary adjuvant system that combines delta-inulin (a plant-derived polysaccharide) with a CpG oligonucleotide (a Toll-like receptor 9 agonist). This combination is intended to enhance both humoral and cellular immune responses, potentially overcoming the lack of response seen in some individuals with standard HBV vaccines and providing a therapeutic effect in chronic HBV carriers.
- Brand names
- Hepadvax
- Other names
- preS-HBsAg + Advax-3delta-inulin/CpG-adjuvanted preS HBV vaccineHepaVax-3HepaVax3HepaVax 3
02
Targets
HBsAg (Hepatitis B surface antigen)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on preS hepatitis B surface antigen + Advax-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on preS hepatitis B surface antigen + Advax-3.